India
· Delayed Price · Currency is INR Ipca Laboratories Statistics
Total Valuation
Ipca Laboratories has a market cap or net worth of INR 401.49 billion. The enterprise value is 418.65 billion.
| Market Cap | 401.49B |
| Enterprise Value | 418.65B |
Important Dates
The next estimated earnings date is Thursday, February 13, 2025.
| Earnings Date | Feb 13, 2025 |
| Ex-Dividend Date | Nov 27, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.05% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 135.44M |
Valuation Ratios
The trailing PE ratio is 60.72.
| PE Ratio | 60.72 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 6.21 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.99, with an EV/FCF ratio of 46.63.
| EV / Earnings | 63.32 |
| EV / Sales | 4.91 |
| EV / EBITDA | 28.99 |
| EV / EBIT | 39.68 |
| EV / FCF | 46.63 |
Financial Position
The company has a current ratio of 2.37, with a Debt / Equity ratio of 0.15.
| Current Ratio | 2.37 |
| Quick Ratio | 1.13 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 0.83 |
| Debt / FCF | 1.34 |
| Interest Coverage | 9.76 |
Financial Efficiency
Return on equity (ROE) is 8.51% and return on invested capital (ROIC) is 7.01%.
| Return on Equity (ROE) | 8.51% |
| Return on Assets (ROA) | 5.80% |
| Return on Capital (ROIC) | 7.01% |
| Revenue Per Employee | 4.92M |
| Profits Per Employee | 381,419 |
| Employee Count | 17,335 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 1.23 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +43.02% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +43.02% |
| 50-Day Moving Average | 1,572.02 |
| 200-Day Moving Average | 1,363.32 |
| Relative Strength Index (RSI) | 55.48 |
| Average Volume (20 Days) | 268,611 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ipca Laboratories had revenue of INR 85.34 billion and earned 6.61 billion in profits. Earnings per share was 26.05.
| Revenue | 85.34B |
| Gross Profit | 54.78B |
| Operating Income | 10.58B |
| Pretax Income | 9.98B |
| Net Income | 6.61B |
| EBITDA | 14.30B |
| EBIT | 10.58B |
| Earnings Per Share (EPS) | 26.05 |
Balance Sheet
The company has 9.03 billion in cash and 12.02 billion in debt, giving a net cash position of -2.99 billion.
| Cash & Cash Equivalents | 9.03B |
| Total Debt | 12.02B |
| Net Cash | -2.99B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 81.18B |
| Book Value Per Share | 264.24 |
| Working Capital | 32.85B |
Cash Flow
In the last 12 months, operating cash flow was 14.41 billion and capital expenditures -5.44 billion, giving a free cash flow of 8.98 billion.
| Operating Cash Flow | 14.41B |
| Capital Expenditures | -5.44B |
| Free Cash Flow | 8.98B |
| FCF Per Share | n/a |
Margins
Gross margin is 64.18%, with operating and profit margins of 12.39% and 7.75%.
| Gross Margin | 64.18% |
| Operating Margin | 12.39% |
| Pretax Margin | 11.69% |
| Profit Margin | 7.75% |
| EBITDA Margin | 16.76% |
| EBIT Margin | 12.39% |
| FCF Margin | 10.52% |
Dividends & Yields
Ipca Laboratories does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | 100.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 15.35% |
| Buyback Yield | -0.05% |
| Shareholder Yield | -0.05% |
| Earnings Yield | 1.64% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on January 10, 2022. It was a forward split with a ratio of 2.
| Last Split Date | Jan 10, 2022 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |